Impact of viral sensitizer-enhanced oncolytic virus immunotherapy on the anti-tumor immune response

• DOI: 10.4049/jimmunol.204.supp.169.21
• Publication Date: 2023-01-01T11:29:31Z
• Authors: Nouf N Alluqmani; Anabel Bergeron; Andrew Chen; Sarwat Khan; Nicole Forbes; Rozanne Arulanandam; Christiano Souza; Debbi C Crans; Jean-Simon Diallo
• Keywords: Cancer Immunotherapy

Abstract Oncolytic viruses (OVs) have emerged as promising anticancer treatment platforms, able to specifically replicate in and kill cancer cells. OVs also immunostimulatory effects, promoting antitumor immune responses, several strategies been developed combination with stimulate cancer-specific responses. Viral sensitizers (VSes) are molecules that alter the tumor antiviral response order improve efficacy of OVs. Such compounds can OV spread, transgene expression, promote long-term immunity various models. A major objective our study is investigate impact VSes on T-cells other cells context therapy vaccination employing Results date, significantly therapeutic syngeneic murine carcinoma Additionally, we performed peptide-MHC-class I pentameric complexes staining evaluate kinetics T cell mediated anti-tumor vivo, data illustrated this induced production antigen specific CD8+ We screened for chemokine cytokine secretion using multiplex assay, found significant increases IFN-γ, GM-CSF, IL-12, 24 hour 5 days post treatment. currently aim phenotype microenvironment understanding mechanism modulates flow cytometry. anticipate unraveling immunological will lead better contributing its ability successfully translate findings clinic.